Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02KKA
|
|||
| Former ID |
DCL000569
|
|||
| Drug Name |
MK-1775
|
|||
| Synonyms |
MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1], [2] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [3] | ||
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H32N8O2
|
|||
| Canonical SMILES |
CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O
|
|||
| InChI |
1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)
|
|||
| InChIKey |
BKWJAKQVGHWELA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 955365-80-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
50087297, 57153446, 103905025, 119526878, 123055428, 124757316, 125164120, 134339129, 136340195, 136348241, 136367536, 137276027, 140608871, 144116226, 152258293, 160647132, 162012024, 162037646, 162127566, 162202673, 163643009, 163907976, 164042069, 172087065, 176251781, 177748702, 184823454, 198966582, 219813764, 223366035, 223375310, 223623577, 223705090, 227708523, 242060384, 242514641, 244576507, 249859269, 250211323, 252065946, 252110173, 252160193, 252215807, 252442192, 252451627
|
|||
| ChEBI ID |
CHEBI:91414
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Wee1-like protein kinase (WEE1) | Target Info | Inhibitor | [4], [5] |
| KEGG Pathway | Cell cycle | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | PLK1 signaling events | |||
| Reactome | Polo-like kinase mediated events | |||
| Cyclin E associated events during G1/S transition | ||||
| Cyclin A/B1 associated events during G2/M transition | ||||
| G2/M DNA replication checkpoint | ||||
| Cyclin A:Cdk2-associated events at S phase entry | ||||
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | ||||
| Factors involved in megakaryocyte development and platelet production | ||||
| WikiPathways | G1 to S cell cycle control | |||
| S Phase | ||||
| Retinoblastoma (RB) in Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Mitotic G2-G2/M phases | ||||
| Mitotic G1-G1/S phases | ||||
| Factors involved in megakaryocyte development and platelet production | ||||
| Cell Cycle | ||||
| Cell Cycle Checkpoints | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702). | |||
| REF 2 | Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther. 2011 Dec;10(12):2405-14. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. | |||
| REF 5 | Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer. 2009 Jun 8;8:34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.